ArticleOncoscience2015

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification.

Umut Disel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.